Ian Koplin - Profile and Journalist Details

Find journalists that align with your industry, location and vision. Unlock Ian Koplin's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.

Get connected with journalists today
Ian Koplin

Ian Koplin

Verified

Editor, ABF Journal

Philadelphia

Final Covers

futures markets commodity markets financebusiness stock markets

Doesn’t Cover

Portfolio management, defined benefit plans

Journalist Type

Seniority Positions

Medium Formats

Content

Total articles 6848

  • BlackRock Provides $55MM in Term Loan Financing to Akebia Therapeutics

    By Ian Koplin Verified| ABF Journal Verified Biopharmaceutical company Akebia Therapeutics closed a term loan facility with funds and accounts managed by BlackRock that provides for up to $55 million in borrowing capacity available in three tranches. At the closing, Akebia drew the first tranche of $37 million and used the proceeds to pay down $35 million of principal outstanding from a loan agreement with Pharmakon Advisors, the investment manager of the BioPharma Credit funds, plus interest and fees.

    By Ian Koplin Verified · ABF Journal

    Jan. 31, 2024

  • Citizens Business Conditions Index Rose in Q4/23, Indicating Optimism About US Economy

    By Ian Koplin Verified| ABF Journal Verified Citizens Business Conditions Index rose to 51.8 in Q4/23, supported by continued resilience in the labor market and consumer trends. The second consecutive quarterly reading above 50 indicates that the U.S. economy exited 2023 with momentum, with signs of moderating inflation supporting optimism for a soft landing.

    By Ian Koplin Verified · ABF Journal

    Jan. 31, 2024

  • BlackRock Provides $55MM in Term Loan Financing to Akebia Therapeutics

    By Ian Koplin Verified| ABF Journal Verified Biopharmaceutical company Akebia Therapeutics closed a term loan facility with funds and accounts managed by BlackRock that provides for up to $55 million in borrowing capacity available in three tranches. At the closing, Akebia drew the first tranche of $37 million and used the proceeds to pay down $35 million of principal outstanding from a loan agreement with Pharmakon Advisors, the investment manager of the BioPharma Credit funds, plus interest and fees.

    By Ian Koplin Verified · ABF Journal

    Jan. 31, 2024

As seen in

Company Info

ABF Journal

ABF Journal is a monthly trade journal dedicated to the commercial finance industry. As part of RAM Holdings' brands, it has been a key player in publishing, talent development, research, and events for over 50 years. The journal provides insights and updates on the latest trends and developments, catering specifically to commercial finance professionals. The primary offering of ABF Journal is its monthly publication, which includes articles, analysis, and news relevant to the commercial finance sector. It serves a diverse audience of approximately 18,000 industry professionals, including executives, private equity investors, and investment bankers. The journal also features listings and profiles of various companies in the sector, highlighting industry leaders and their achievements.